FDA Approves Vertex’s JOURNAVX™ For Safe, Non-Opioid Pain Relief

Vertex Pharmaceuticals announced the FDA approval for their new pain medication, JOURNAVX™ (suzetrigine). It’s a non-opioid pill designed to help adults manage moderate-to-severe acute pain. It targets pain signals very precisely, offering relief without the risk of addiction that comes with opioids. Plus, it’s been shown to work well and be well-tolerated. JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.

“Today’s approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year. With the approval of JOURNAVX, a non-opioid, pain signal inhibitor and the first new class of pain medicine approved in more than 20 years, we have the opportunity to change the paradigm of acute pain management and establish a new standard of care, ”said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.=

Jessica Oswald, M.D., M.P.H., Associate Physician in Emergency Medicine and Pain Medicine in San Diego and Vertex Acute Pain Steering Committee Member, said in a statment, “This is an incredible day for patients and physicians alike who now have an approved non-opioid treatment that delivers effective acute pain relief and a favorable safety profile without addictive potential. I believe JOURNAVX could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids have been so desperately needed.”